Cardiovascular risk assessment in daily clinical practice: when and how to use a risk score

被引:0
|
作者
Panattoni, Germana [1 ]
Desimone, Pietro [2 ]
Toto, Federica [1 ]
Meringolo, Federica [3 ]
Jacomelli, Ilaria [1 ]
Rebecchi, Marco [1 ]
Cicogna, Francesco [1 ]
Calo, Leonardo [1 ]
机构
[1] Policlin Casilino, Div Cardiol, Via Casilina 1049, I-00169 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Cardiol, Viale Oxford 81, I-00133 Rome, Italy
[3] Catholic Univ Our Lady Good Counsel, Fac Med, Dept Biomed Sci, Tirana 1000, Albania
关键词
Atherosclerotic cardiovascular disease; Cardiovascular risk calculator; 10-Year risk of fatal and non-fatal CVD events; Lifetime risk; Residual risk; EUROPEAN-SOCIETY; ESC GUIDELINES; DISEASE; EVENTS; PREDICTION;
D O I
10.1093/eurheartjsupp/suae100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular diseases (CVDs) remain a major cause of morbidity and mortality worldwide. The European Society of Cardiology Guidelines encourage the use of risk prediction models to enhance an adequate management of cardiovascular risk factors and the implementation of healthy behaviours. In primary prevention, estimating CVD risk is used to identify patients at high risk in order to enhance preventive strategies and decrease the incidence of unfavourable events and pre-mature cardiovascular deaths. Risk models integrate information on several conventional risk factors and estimate individual risk over a 10-year period. In addition to conventional risk factors, emerging non-traditional markers should be considered and mentioned in risk stratification. In secondary prevention, optimal management of patients include evaluation of residual CVD risk. The 10-year risk of recurrent events is not the same for all patients. The identification of high-risk patients is mandatory to prevent recurrent events and to allow to engage intensive treatments and follow-up strategies, representing an opportunity for major public health gain. This review provides a guide to evaluate which CVD risk score is appropriate for use in different settings in clinical practice.
引用
收藏
页码:i16 / i21
页数:6
相关论文
共 50 条
  • [41] Cardiovascular Risk in HIV-Infected and Uninfected Postmenopausal Minority Women: Use of the Framingham Risk Score
    Cortes, Yamnia I.
    Reame, Nancy
    Zeana, Cosmina
    Jia, Haomiao
    Ferris, David C.
    Shane, Elizabeth
    Yin, Michael T.
    JOURNAL OF WOMENS HEALTH, 2017, 26 (03) : 241 - 248
  • [42] Cardiovascular Health Score and Lifetime Risk of Cardiovascular Disease The Cardiovascular Lifetime Risk Pooling Project
    Bundy, Joshua D.
    Ning, Hongyan
    Zhong, Victor W.
    Paluch, Amanda E.
    Lloyd-Jones, Donald M.
    Wilkins, John T.
    Allen, Norrina B.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2020, 13 (07): : 425 - 435
  • [43] Simple Risk Score for the Assessment of Absolute Fracture Risk in General Practice Based on Two Longitudinal Studies
    Pluijm, Saskia M. F.
    Koes, Bart
    de Laet, Chris
    Van Schoor, Natasja M.
    Kuchuk, Natalia O.
    Rivadeneira, Fernando
    Mackenbach, Johan P.
    Lips, Paul
    Pols, Huibert A.
    Steyerberg, Ewout W.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (05) : 768 - 774
  • [44] Clinical Applicability of the Framingham 30-Year Risk Score. Usefulness in Cardiovascular Risk Stratification and the Diagnosis of Carotid Atherosclerotic Plaque
    Masson, Walter
    Siniawski, Daniel
    Krauss, Juan
    Cagide, Arturo
    REVISTA ESPANOLA DE CARDIOLOGIA, 2011, 64 (04): : 305 - 311
  • [45] How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?
    Hadley, Trevor D.
    Agha, Ali M.
    Ballantyne, Christie M.
    CURRENT ATHEROSCLEROSIS REPORTS, 2021, 23 (06)
  • [46] Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice
    Giles, Jon T.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2015, 29 (4-5): : 597 - 613
  • [47] Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment
    Yeboah, Joseph
    Young, Rebekah
    McClelland, Robyn L.
    Delaney, Joseph C.
    Polonsky, Tamar S.
    Dawood, Farah Z.
    Blaha, Michael J.
    Miedema, Michael D.
    Sibley, Christopher T.
    Carr, J. Jeffrey
    Burke, Gregory L.
    Goff, David C., Jr.
    Psaty, Bruce M.
    Greenland, Philip
    Herrington, David M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (02) : 139 - 147
  • [48] Implementation of Risk-Stratified Breast Cancer Prevention With a Polygenic Risk Score Test in Clinical Practice
    Padrik, Peeter
    Puustusmaa, Mikk
    Tonisson, Neeme
    Kolk, Berit
    Saar, Regina
    Padrik, Anna
    Tasa, Tonis
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2023, 17
  • [49] Association between Cardiovascular Risk Assessment by SCORE2 and Diverticulosis: A Cross-Sectional Analysis
    Voelkerer, Andreas
    Wernly, Sarah
    Semmler, Georg
    Flamm, Maria
    Radzikowski, Konrad
    Datz, Leonora
    Goetz, Nikolaus
    Hofer, Hannah
    Aigner, Elmar
    Datz, Christian
    Wernly, Bernhard
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (08):
  • [50] Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA)
    Rodriguez-Artalejo, Fernando
    Guallar, Eliseo
    Borghi, Claudio
    Dallongeville, Jean
    De Backer, Guy
    Halcox, Julian P.
    Hernandez-Vecino, Ramon
    Javier Jimenez, Francisco
    Masso-Gonzalez, Elvira L.
    Perk, Joep
    Gabriel Steg, Philippe
    Banegas, Jose R.
    BMC PUBLIC HEALTH, 2010, 10